

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
WO 01/98306 A1(51) International Patent Classification<sup>7</sup>: C07D 491/06,  
A61K 31/435, C07D 491/04, A61P 1/00

(21) International Application Number: PCT/EP01/06749

(22) International Filing Date: 13 June 2001 (13.06.2001)

(25) Filing Language: English

(26) Publication Language: English







(30) Priority Data:  
00202180.6 22 June 2000 (22.06.2000) EP(71) Applicant (for all designated States except US):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Janssen  
Pharmaceutica N.V., Patent Department, Turnhoutseweg  
30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VAN EMELEN,  
Kristof [BE/BE]; c/o Janssen Pharmaceutica N.V.,  
Turnhoutseweg 30, B-2340 Beerse (BE). DE BRUYN,  
Marcel, Frans, Leopold [BE/BE]; c/o Janssen Pha-  
rmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse  
(BE). ALCÁZAR-VACA, Manuel, Jesús [ES/ES]; c/o  
Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de  
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042Madrid (ES). ANDRÉS-GIL, José, Ignacio [ES/ES]; c/o  
Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de  
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042  
Madrid (ES). FERNÁNDEZ-GADEA, Francisco, Javier  
[ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson &  
Johnson, Paseo de las Doce Estrellas, 5-7, Campo de las  
Naciones, E-28042 Madrid (ES). MATESANZ-BALLES-  
TEROS, María, Encarnacion [ES/ES]; c/o Janssen Cilag  
S.A., Edificio Johnson & Johnson, Paseo de las Doce Es-  
trellas, 5-7, Campo de las Naciones, E-28042 Madrid (ES).  
BARTOLOMÉ-NEBREDA, José, Manuel [ES/ES]; c/o  
Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de  
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042  
Madrid (ES).(74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V.,  
Turnhoutseweg 30, B-2340 Beerse (BE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION



A1

WO 01/98306

(57) Abstract: The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein  $a^1=a^2=a^3=a^4$  is a bivalent radical wherein one or two of  $a^1$  to  $a^4$  are nitrogen and the remaining  $a^1$  to  $a^4$  are  $-CH=$ ;  $-Z^1-Z^2$  is a bivalent radical;  $-A-$  is a bivalent radical of formula  $-N(R^6)-Alk^2-$  or a 5, 6 or 7-membered saturated heterocycle containing one or two nitrogen atoms;  $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from hydrogen,  $C_{1-6}$ alkyl, hydroxy, halo and the like;  $Alk^1$  and  $Alk^2$  are optionally substituted  $C_{1-6}$ alkanediyl;  $R^5$  is a radical of formula (d-1), (d-2), (d-3), (d-4), (d-5) wherein  $n$  is 1 or 2;  $p^1$  is 0, and  $p^2$  is 1 or 2; or  $p^1$  is 1 or 2, and  $p^2$  is 0;  $X$  is oxygen, sulfur or  $=NR^9$ ;  $Y^2$  is oxygen or sulfur;  $R^7$  is hydrogen,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl, phenyl or phenylmethyl;  $R^8$  is  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl phenyl or phenylmethyl;  $R^9$  is cyano,  $C_{1-6}$ alkyl,  $C_{3-6}$ cyclo-alkyl,  $C_{1-6}$ alkyloxycarbonyl or aminocarbonyl;  $R^{10}$  is hydrogen or  $C_{1-6}$ alkyl; and  $Q$  is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to disturbed fundic accommodation.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION

5 The present invention is concerned with novel compounds of formula (I) having fundic relaxation properties. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds to restore disturbed fundic accommodation.

10 DE-2,400,094, published on 18 July 1974, discloses 1-[1-[2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl]-4-piperidyl-2-benzimidazolinones possessing blood pressure lowering activity.

15 DE-2,852,945, published on 26 June 1980, discloses benzodioaxanylhydroxyethyl-piperidylimidazolidinones having antihypertensive activity.

15 EP-0,004,358, published on 3 October 1979, discloses *N*-oxacycloalkylalkylpiperidines useful as antidepressants and psychostimulants.

20 EP-0,048,218, published on 24 March 1982, discloses *N*-oxides of *N*-oxacycloalkyl-alkylpiperidines having antidepressant activity.


25 WO-93/17017, published on 2 September 1993, discloses [(benzodioxane, benzofuran or benzopyran)alkylamino]alkyl-substituted guanidine as selective vasoconstrictors useful to treat conditions related to vasodilatation such as, e.g., migraine, cluster headache and headache associated with vascular disorders.

WO-95/053837, published on 23 February 1995, encompasses dihydrobenzopyran-pyrimidine derivatives also having vasoconstrictive activity.

30 WO-97/28157, published on 7 August 1997, discloses aminomethylchroman derivatives as  $\alpha_2$ -adrenergic receptor antagonists useful in the treatment of degenerative neurological conditions.

35 The compounds of the present invention differ from the cited art-known compounds structurally, by the nature of the bivalent radical  $-a^1=a^2-a^3=a^4-$ , the  $R^5$  substituent, and pharmacologically by the fact that, unexpectedly, these compounds have fundic relaxation properties. Furthermore, the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity.

The present invention concerns compounds of formula (I)



5

a stereochemically isomeric form thereof, an *N*-oxide form thereof, a pharmaceutically acceptable acid addition salt thereof, or a quaternary ammonium salt thereof, wherein  $-a^1-a^2-a^3-a^4-$  is a bivalent radical of formula

-Z<sup>1</sup>-Z<sup>2</sup>- is a bivalent radical of formula

20	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -	(b-1),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-O-	(b-2),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -O-	(b-3),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -S-	(b-4),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -NH-	(b-5),
25	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -CH <sub>2</sub> -	(b-6),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -	(b-7),
	-Y <sup>1</sup> -C(R <sup>4</sup> )=CH-	(b-8),
	-Y <sup>1</sup> -C(R <sup>4</sup> )=CH-CH <sub>2</sub> -	(b-9),
	-Y <sup>1</sup> -CH(R <sup>4</sup> )-CH=CH-	(b-10),
30	-Y <sup>1</sup> -C(R <sup>4</sup> )=CH-CH <sub>2</sub> -CH <sub>2</sub> -	(b-11), or
	-Y <sup>1</sup> -CH <sub>2</sub> -CH(R <sup>4</sup> ) -	(b-12),

wherein, where possible, optionally one or two hydrogen atoms on the same or a different carbon or nitrogen atom may be replaced by hydroxyl.

$C_{1-4}alkyloxyC_{1-4}alkyl$ ,  $C_{1-4}alkylcarbonyl$ , or  $C_{1-6}alkyl$  optionally substituted with halo, hydroxy,  $C_{3-6}cycloalkyl$ , or phenyl:


$Y^1$  is oxygen or sulfur;

Alk<sup>1</sup> is C<sub>1-4</sub>alkylcarbonyl, carbonylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonylC<sub>1-4</sub>alkyl, carbonyl, or C<sub>1-6</sub>alkanediyl optionally substituted with hydroxy, halo, amino, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, hydroxycarbonyl, C<sub>1-4</sub>alkyloxycarbonyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, 5 C<sub>1-4</sub>alkylcarbonyloxy, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>1-4</sub>alkyloxyimino, phenylC<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkyloxycarbonylC<sub>1-6</sub>alkenyl, cyanoC<sub>1-6</sub>alkenyl or C<sub>1-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;


R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, 10 C<sub>1-6</sub>alkyloxy, hydroxycarbonyl, trihalomethyl, trihalomethoxy, halo, hydroxy, cyano, nitro, amino, C<sub>1-6</sub>alkylcarbonylamino, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxy, aminocarbonyl, mono- or di(C<sub>1-6</sub>alkyl)aminocarbonyl, aminoC<sub>1-6</sub>alkyl, mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, 15 C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, or C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;

R<sup>4</sup> is hydrogen, hydroxycarbonyl, phenyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, N-pyroridinylcarbonyl, N-piperidinylcarbonyl, N-homopiperidinylcarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkyloxycarbonylC<sub>1-4</sub>alkyl, 20 C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, or C<sub>1-6</sub>alkyl optionally substituted with hydroxy, cyano, amino, phenyl, mono- or di(C<sub>1-4</sub>alkyl)amino, or mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl;


17 -A- is a bivalent radical of formula




(c-1)




(c-2)




(c-3)




(c-4)



(c-5)



(c-6)




(c-7)

wherein m is 0 or 1;

Alk<sup>2</sup> is a bivalent radical independently selected from C<sub>1-4</sub>alkylcarbonylC<sub>1-4</sub>alkyl; phenyl; C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy; C<sub>3-8</sub>cycloalkanediyl optionally substituted with one or more halo, hydroxy, hydroxycarbonyl, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, phenyl; or C<sub>1-6</sub>alkyl optionally substituted with one or more hydroxy, halo, amino, hydroxycarbonyl, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>3-6</sub>cycloalkyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, or C<sub>1-6</sub>alkyl wherein the C<sub>1-6</sub>alkyl together with the carbon atom to which it is attached may form a C<sub>3-6</sub>cycloalkyl;

R<sup>6</sup> is hydrogen, C<sub>1-4</sub>alkyl, halo, hydroxy, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyl, amino, hydroxycarbonyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, or C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;

R<sup>5</sup> is a radical of formula



wherein n is 1 or 2;

p<sup>1</sup> is 0, and p<sup>2</sup> is 1 or 2; or p<sup>1</sup> is 1 or 2, and p<sup>2</sup> is 0;

X is oxygen, sulfur, NR<sup>9</sup> or CHNO<sub>2</sub>;

Y<sup>2</sup> is oxygen or sulfur;

R<sup>7</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl or phenylmethyl;

R<sup>8</sup> is C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl or phenylmethyl;

R<sup>9</sup> is cyano, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-6</sub>alkyloxycarbonyl or aminocarbonyl;

R<sup>10</sup> is hydrogen or C<sub>1-6</sub>alkyl;


or R<sup>9</sup> and R<sup>10</sup> taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, or morpholinyl group, optionally substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy; and

Q is a bivalent radical of formula

-CH <sub>2</sub> -CH <sub>2</sub> -	(e-1),	-CO-CH <sub>2</sub> -	(e-6),
-CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -	(e-2),	-(CH <sub>2</sub> ) <sub>2</sub> -CO-	(e-7),
-CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -	(e-3),	-CO-(CH <sub>2</sub> ) <sub>2</sub> -	(e-8),
-CH=CH-	(e-4),	-CO-CH <sub>2</sub> -CO-	(e-9),
-CH <sub>2</sub> -CO-	(e-5),	-CH <sub>2</sub> -CO-CH <sub>2</sub> -	(e-10),

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C<sub>1-4</sub>alkyl, hydroxy or phenyl, or

Q is a bivalent radical of formula



(e-11)

(e-12)

10


As used in the foregoing definitions halo is generic to fluoro, chloro, bromo and iodo; C<sub>1-4</sub>alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methyl-ethyl, 2-methylpropyl and the like; C<sub>1-6</sub>alkyl is meant to include C<sub>1-4</sub>alkyl and the

15 higher homologues thereof having 5 or 6 carbon atoms, such as, for example, 2-methylbutyl, pentyl, hexyl and the like; C<sub>3-6</sub>cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; C<sub>3-6</sub>alkenyl defines straight and branched chain unsaturated hydrocarbon radicals having from 3 to 6 carbon atoms, such as propenyl, butenyl, pentenyl or hexenyl; C<sub>1-2</sub>alkanediyl defines methylene or 1,2-ethanediyl;

20 C<sub>1-3</sub>alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 1 to 3 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, and the branched isomers thereof; C<sub>1-5</sub>alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 1 to 5 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl,

25 1,5-pentanediyI, and the branched isomers thereof; C<sub>1-6</sub>alkanediyl includes C<sub>1-5</sub>alkanediyl and the higher homologues thereof having 6 carbon atoms such as, for example, 1,6-hexanediyI and the like. The term "CO" refers to a carbonyl group.

Some examples of the R<sup>5</sup> moiety are :



5

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all 10 diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of formula (I) are 15 obviously intended to be embraced within the scope of this invention.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid 20 addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (*i.e.* ethanedioic), malonic, succinic (*i.e.* butanedioic acid), 25 maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

Quaternary ammonium salts of compounds of formula (I) as used herein defines which 5 the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A 10 quaternary ammonium salt has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be made using ion exchange resin columns.

The term addition salt as used hereinabove also comprises the solvates which the 15 compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

The *N*-oxide forms of the compounds of formula (I), which may be prepared in art-known manners, are meant to comprise those compounds of formula (I) wherein a 20 nitrogen atom is oxidized to the *N*-oxide.

The absolute stereochemical configuration of some compounds of formula (I) and of 25 intermediates used in their preparation, was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" isomeric forms can be unambiguously characterized by for instance their optical rotation in case "A" and "B" have an enantiomeric relationship. A person skilled in the art is able to determine the absolute 30 configuration of such compounds using art-known methods, e.g. X-ray diffraction.

30 A first group of compounds are those compounds of formula (I) wherein the bivalent radical  $-Z^1-Z^2-$  is of formula (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8), (b-9), (b-10), or (b-11).

35 Interesting compounds are those compounds of formula (I) wherein one or more of the following restrictions apply :  
a) the bivalent radical  $-Z^1-Z^2-$  is of formula (b-1), or (b-2); or

- b) the bivalent radical  $-Z^1-Z^2-$  is of formula (b-2), (b-3), (b-4), or (b-5); in particular the bivalent radical  $-Z^1-Z^2-$  is of formula (b-2) or (b-3); or
- c) the bivalent radical  $-Z^1-Z^2-$  is of formula (b-3);
- d) the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1), (a-2) or (a-4); in particular  $-a^1=a^2-a^3=a^4-$  is of formula (a-1);
- 5 e) the bivalent radical  $-A-$  is of formula (c-1) or (c-2);
- f)  $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from hydrogen,  $C_{1-6}$ alkyl, hydroxy or halo;
- g)  $R^4$  is hydrogen;
- 10 h)  $Alk^1$  is  $C_{1-2}$ alkanediyl optionally substituted with hydroxy, in particular  $Alk^1$  is  $-CH_2-$ ;
- i)  $Alk^2$  is  $C_{1-3}$ alkanediyl optionally substituted with hydroxy, in particular  $Alk^2$  is  $-(CH_2)_3-$  or  $-CH_2-CHOH-CH_2-$ ; and/or
- j)  $R^6$  is hydrogen of phenylmethyl.

15 Particular compounds of formula (I) are those compounds of formula (I) wherein the bivalent radical  $-Z^1-Z^2-$  is of formula  $-O-CH_2-CH_2-O-$  and the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1).

20 Other particular compounds are those compounds of formula (I) wherein the bivalent radical  $-Z^1-Z^2-$  is of formula  $-O-CH_2-O-$  and the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1).

25 Preferred compounds are those compounds of formula (I) wherein  $R^5$  is a radical of formula (d-1) wherein X is oxygen,  $R^7$  is hydrogen, and Q is (e-2)

More preferred compounds are those compounds of formula (I) wherein the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1), (a-2) or (a-4); the bivalent radical  $-Z^1-Z^2-$  is of formula (b-1), (b-2) or (b-4) wherein  $R^4$  is hydrogen;  $Alk^1$  is  $-CH_2-$ ; the bivalent radical  $-A-$  is of formula (c-1) or (c-2); and  $R^5$  is a radical of formula (d-1) wherein X is oxygen,  $R^7$  is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

30 Other more preferred compounds are those compounds of formula (I) wherein the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1), (a-2) or (a-4); the bivalent radical  $-Z^1-Z^2-$  is of formula (b-1), (b-2) or (b-4) wherein  $R^4$  is hydrogen;  $Alk^1$  is  $-CH_2-$ ; the bivalent radical  $-A-$  is of formula (c-2) wherein  $R^6$  is hydroxymethyl; and  $R^5$  is a radical of formula (d-1) wherein X is oxygen,  $R^7$  is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

Still other more preferred compounds are those compounds of formula (I) wherein the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1), (a-2) or (a-4); the bivalent radical  $-Z^1-Z^2-$  is of formula (b-1), (b-2) or (b-4) wherein  $R^4$  is hydrogen;  $Alk^1$  is  $-CH_2-$ ; the bivalent radical  $-A-$  is of formula  $-CH_2-CHOH-CH_2-$ ; and  $R^5$  is a radical of formula (d-1) wherein X is oxygen,  $R^7$  is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

Most preferred compounds are those compounds of formula (I) wherein the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1); the bivalent radical  $-Z^1-Z^2-$  is of formula (b-3) wherein  $Y^1$  is O and  $R^4$  is hydrogen; the bivalent radical  $Alk^1$  is  $-CH_2-$ ; the bivalent radical A is of formula (c-2) wherein m is the integer 0; and radical  $R^5$  is of formula (d-1) wherein the bivalent radical Q is of formula (e-1) or (e-2).

Other most preferred compounds are those compounds of formula (I) wherein the bivalent radical  $-a^1=a^2-a^3=a^4-$  is of formula (a-1); the bivalent radical  $-Z^1-Z^2-$  is of formula (b-3) wherein  $Y^1$  is O and  $R^4$  is hydrogen; the bivalent radical  $Alk^1$  is  $-CH_2-$ ; the bivalent radical A is of formula (c-1) wherein  $Alk^2$  is  $-(CH_2)_3-$ ; and radical  $R^5$  is of formula (d-1) wherein the bivalent radical Q is of formula (e-5) or (e-7).

20 Preferable compounds are

1-[1-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]-4-piperidinyl]-2-imidazolidinone;

1-[1-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]-4-piperidinyl]tetrahydro-2(1*H*)-pyrimidinone;

25 1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]amino]propyl]dihydro-2,4(1*H*,3*H*)-pyrimidinedione; and


1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]amino]propyl]-2,4-imidazolidinedione, a pharmaceutically acceptable acid addition salt, a stereochemically isomeric form, or an *N*-oxide form thereof. In particular, the

30 (S)-stereoisomers of the above four compounds are preferred.


The compounds of the present invention can generally be prepared by alkylating an intermediate of formula (III) with an intermediate of formula (II), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo, iodo, or in some instances W may also be a sulfonyloxy group, e.g. methanesulfonyloxy, benzenesulfonyloxy, trifluoromethanesulfonyloxy and the like reactive leaving groups. The reaction can be performed in a reaction-inert solvent such as, for example, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base such as,

-10-

for example, sodium carbonate, potassium carbonate, calcium oxide or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out in an autoclave at an increased pressure.




Compounds of formula (I) can also be prepared by reductively alkylating an intermediate of formula (IV), wherein Alk<sup>1</sup> represents a direct bond or C<sub>1-5</sub>alkanediyl, following art-known reductive alkylation procedures with an intermediate of formula (III).




15 Said reductive alkylation can be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of a reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Alternatively, compounds of formula (I) can also be prepared by reacting an acid chloride of formula (V), wherein  $\text{Alk}^1$  represents  $\text{C}_{1-5}\text{alkanediyl}$  or a direct bond, with an intermediate of formula (III) under suitable reaction conditions.



Said reaction can be performed under hydrogenation conditions with hydrogen gas in the presence of a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal, in a suitable solvent such as, for example, ethyl acetate, and in the presence of magnesiumoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g. thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Compounds of formula (I-a), defined as compounds of formula (I) wherein the bivalent radical  $-A-$  represents  $-NR^6-CH_2-CH(OH)-CH_2-$ , can be prepared by reacting 20 intermediates of formula (VI) with intermediates of formula (VII) in a reaction-inert solvent, such as methanol, and optionally in the presence of an anorganic base, such as sodium carbonate.



25

The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions. For instance, compounds of formula (I) wherein R<sup>6</sup> is phenylmethyl can be converted to the

corresponding compounds of formula (I) wherein R<sup>6</sup> is hydrogen by art-known debenzylation procedures. Said debenzylation can be performed following art-known procedures such as catalytic hydrogenation using appropriate catalysts, e.g. platinum on charcoal, palladium on charcoal, in appropriate solvents such as methanol, ethanol, 5 2-propanol, diethyl ether, tetrahydrofuran, and the like. Furthermore, compounds of formula (I) wherein R<sup>6</sup> is hydrogen may be alkylated using art-known procedures such as, e.g. reductive N-alkylation with a suitable aldehyde or ketone.

The compounds of formula (I) may also be converted to the corresponding N-oxide 10 forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; 15 appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarbo-peroxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzene-carboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 20 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

The starting materials and some of the intermediates are known compounds and are 25 commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, some intermediates of formula (III) can be prepared as described in Examples A.4 and A.5 of WO-99/29687.

Compounds of formula (I) and some of the intermediates may have one or more 30 stereogenic centers in their structure, present in a R or a S configuration, such as, e.g. the carbon atom bearing the R<sup>4</sup> substituent, and the carbon atom linked to the -Alk<sup>1</sup>-A-R<sup>5</sup> moiety.

The compounds of formula (I) as prepared in the hereinabove described processes may 35 be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are

liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting

5 materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

10 The compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable salts and stereoisomeric forms thereof possess favourable fundic relaxation properties as evidenced in pharmacological example C-1, the "Gastric tone measured by an electronic barostat in conscious dogs"-test.

15 Furthermore, the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity as can be demonstrated in pharmacological example C.2 "Vasoconstrictive activity on basilar artery". Vasoconstrictor activity can cause undesirable side-effects such as coronary effects which can induce chest pain. In addition, the compounds of the present

20 invention have other favourable pharmacokinetic properties in that they have a fast onset and short duration of action, in absence of any CYP<sub>450</sub> 2D6 or 3A4 mediated metabolism.

During the consumption of a meal the fundus, *i.e.* the proximal part of the stomach, relaxes and provides a "reservoir" function. Patients having a disturbed or an impaired adaptive relaxation of the fundus upon food ingestion have been shown to be hypersensitive to gastric distension and display dyspeptic symptoms. Therefore, it is believed that compounds which are able to normalize or restore a disturbed fundic accomodation are useful to relieve patients suffering from said dyspeptic symptoms.

30 In view of the capability of the compounds of the present invention to relax the fundus, the subject compounds are useful to treat disorders or conditions related to a disturbed, hampered or impaired accomodation of the fundus such as, *e.g.* dyspepsia, early satiety, bloating and anorexia.

35 Dyspepsia is described as a motility disorder. Symptoms can be caused by a delayed gastric emptying or by impaired relaxation of the fundus to food ingestion. Warm-blooded animals, including humans, (*generally called herein patients*) suffering from

dyspeptic symptoms as a result of delayed gastric emptying usually have a normal fundic relaxation and can be relieved of their dyspeptic symptoms by administering a prokinetic agent such as, e.g. cisapride. Patients can have dyspeptic symptoms without having a disturbed gastric emptying. Their dyspeptic symptoms may result from a

5      hypercontracted fundus or hypersensitivity resulting in a diminished compliance and abnormalities in the adaptive fundic relaxation. A hypercontracted fundus results in a diminished compliance of the stomach. The "compliance of the stomach" can be expressed as the ratio of the volume of the stomach over the pressure exerted by the stomach wall. The compliance of the stomach relates to the gastric tone, which is the

10     result of the tonic contraction of muscle fibers of the proximal stomach. This proximal part of the stomach, by exerting a regulated tonic contraction (gastric tone), accomplishes the reservoir function of the stomach.

Patients suffering from early satiety cannot finish a normal meal since they feel

15     saturated before they are able to finish said normal meal. Normally when a subject starts eating, the stomach will show an adaptive relaxation, *i.e.* the stomach will relax to accept the food that is ingested. This adaptive relaxation is not possible when the compliance of the stomach is hampered which results in an impaired relaxation of the fundus.

20     In view of the utility of the compounds of formula (I), it follows that the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from disturbed, hampered or impaired accomodation of the fundus to food ingestion. Consequently a method of treatment is

25     provided for relieving patients suffering from conditions, such as, for example, dyspepsia, early satiety, bloating and anorexia.

Hence, the use of a compound of formula (I) as a medicine is provided, and in particular the use of a compound of formula (I) for the manufacture of a medicine for

30     treating conditions involving an disturbed, hampered or impaired accomodation of the fundus to food ingestion. Both prophylactic and therapeutic treatment are envisaged.

The symptoms of impaired fundic relaxation may also arise due to the intake of chemical substances, e.g. Selective Serotonin Re-uptake Inhibitors (SSRI's), such as

35     fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is

combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.

5 For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in

10 which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable

15 additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the

20 corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically

25 discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and

30 segregated multiples thereof.

For oral administration, the pharmaceutical compositions may take the form of solid dose forms, for example, tablets (both swallowable-only and chewable forms), capsules or gelcaps, prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch,

5 polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art.

10 Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means, optionally with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methylcellulose, hydroxypropyl methylcellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

15

20 Pharmaceutically acceptable sweeteners comprise preferably at least one intense sweetener such as saccharin, sodium or calcium saccharin, aspartame, acesulfame potassium, sodium cyclamate, alitame, a dihydrochalcone sweetener, monellin, stevioside or sucralose (4,1',6'-trichloro-4,1',6'-trideoxygalactosucrose), preferably saccharin, sodium or calcium saccharin, and optionally a bulk sweetener such as

25 sorbitol, mannitol, fructose, sucrose, maltose, isomalt, glucose, hydrogenated glucose syrup, xylitol, caramel or honey.

Intense sweeteners are conveniently employed in low concentrations. For example, in the case of sodium saccharin, the concentration may range from 0.04% to 0.1% (w/v)

as Caramel Chocolate flavour, Mint Cool flavour, Fantasy flavour and the like pharmaceutically acceptable strong flavours. Each flavour may be present in the final composition in a concentration ranging from 0.05% to 1% (w/v). Combinations of said strong flavours are advantageously used. Preferably a flavour is used that does not

5 undergo any change or loss of taste and colour under the acidic conditions of the formulation.

The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example 10 subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example as a sparingly soluble salt.

15 The compounds of the invention may be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example by bolus injection or continuous intravenous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as 20 suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as isotonizing, suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water before use.

25 The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration the compounds of the invention may be used, for 30 example, as a liquid spray, as a powder or in the form of drops.

The formulations of the present invention may optionally include an anti-flatulent, such as simethicone, alpha-D-galactosidase and the like.

35 In general it is contemplated that a therapeutically effective amount would be from about 0.001 mg/kg to about 2 mg/kg body weight, preferably from about 0.02 mg/kg to about 0.5 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.

Experimental part

In the procedures described hereinafter the following abbreviations were used : "ACN" stands for acetonitrile and "DCM" stands for dichloromethane.

5 For some chemicals the chemical formula was used, e.g.  $\text{CH}_2\text{Cl}_2$  for dichloromethane,  $\text{CH}_3\text{OH}$  for methanol,  $\text{NH}_3$  for ammonia,  $\text{HCl}$  for hydrochloric acid, and  $\text{NaOH}$  for sodium hydroxide.

In those cases the stereochemically isomeric form which was first isolated is designated 10 as "A", the second as "B", the third one as "C" and the fourth one as "D", without further reference to the actual stereochemical configuration.

A. Preparation of the intermediatesExample A.1

15 Methanesulfonyl chloride (0.012 mol) in DCM (6 ml) was added dropwise to a mixture, cooled on an ice bath, of 2,3 dihydro-1,4-dioxino[2,3-b]pyridine-3-methanol (0.008 mol) and triethylamine (0.016 mol) in DCM (26 ml) and the mixture was stirred at 5°C for 1 hour. The mixture was filtered off, the filtrate was washed with water and extracted. The organic layer was dried, filtered off and evaporated till dryness. The 20 product was used without further purification, yielding 2.17g of ( $\pm$ )-2,3-dihydro-1,4-dioxino[2,3-b]pyridine-3-methanolmethanesulfonate (ester) (intermediate 1).

Example A.2

a) A mixture of 2,3-dihydro-3-[(phenylmethoxy)methyl]-1,4-dioxino[2,3-b]pyridine (0.0638 mol) in  $\text{CH}_3\text{OH}$  (250ml) was hydrogenated with palladium-on-carbon (10%, 2 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. This fraction was purified by HPLC (eluent : ethanol/methanol 60/40; column: Chiraldak AD 20  $\mu\text{m}$ ). Two fractions were collected and the solvent was evaporated, yielding 4.06 g of (S)-2,3-dihydro-1,4-dioxino[2,3-b]-pyridine-3-methanol (intermediate 2-a) ( $[\alpha]_D^{20} = -34.33^\circ$ ;  $c = 25.34 \text{ mg/ 5 ml in methanol}$ ) and 3.81 g of (R)-2,3-dihydro-1,4-dioxino[2,3-b]-pyridine-3-methanol (intermediate 2-b) ( $[\alpha]_D^{20} = +32.74^\circ$ ;  $c = 22.60 \text{ mg/ 5 ml in methanol}$ ).

b) A mixture of intermediate (2-a) (0.023 mol) and triethylamine (0.046 mol) in DCM (40 ml) was stirred at 0°C. A mixture of methanesulfonyl chloride (0.035 mol) in DCM (10 ml) was added dropwise. The mixture was stirred on an ice bath for 2 hours and then washed with  $\text{H}_2\text{O}/\text{NaCl}$ . The organic layer was dried, filtered and the solvent was evaporated. The residue (oil) was solidified in DIPE. The precipitate was filtered off and dried, yielding 5 g of (S)-2,3-dihydro-1,4-dioxino[2,3-b]pyridine-3-methanol

-19-

methanesulfonate (ester) (intermediate 3) ( $[\alpha]_D^{20} = -27.89^\circ$ ;  $c = 25.10 \text{ mg/ 5 ml}$  in methanol; mp.  $136^\circ\text{C}$ ).

Example A.3

5 a) Reaction under a nitrogen atmosphere. NaH 60% (0.4725 mol) was stirred in DMF (225 ml). 2,3-Pyridinediol (0.225 mol) was added portionwise and the mixture was stirred for 30 minutes at room temperature. The reaction mixture was cooled in an ice-water bath and 1,1-dichloro-2-methoxy-2-oxo-ethyl (1.125 mol) was added dropwise. The resulting reaction mixture was stirred for 5 hours at  $95^\circ\text{C}$ , then stirred 10 overnight at room temperature. The cooled crude reaction mixture was treated with water, filtered over Celite and extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : DCM). The desired fractions were collected and the solvent was evaporated, yielding 4.13 g of ( $\pm$ )-methyl 1,3-dioxolo[4,5-b]pyridine-2-carboxylate (intermediate 4).

15 b) Reaction under a nitrogen atmosphere. A solution of intermediate (4) (0.042 mol) in THF (48 ml) was added dropwise to LiAlH<sub>4</sub> (1Min THF) (0.0466 mol) and cooled with an ice-water bath. The resulting reaction mixture was stirred for one hour at room temperature. The reaction mixture was treated carefully with a 10% NH<sub>4</sub>Cl solution and 20 it was diluted with water and ethyl acetate. The reaction mixture was filtered over Celite and the filtrate was extracted. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was washed with DCM, filtered off and dried, yielding 2.78 g of ( $\pm$ )-1,3-dioxolo[4,5-b]pyridine-2-methanol (intermediate 5).

25 c) A solution of intermediate (5) (0.018 mol) and triethyl amine (0.036 mol) in DCM (80 ml) was stirred and cooled with an ice-water bath. Methanesulfonyl chloride (0.027 mol) was added dropwise and the resulting reaction mixture was stirred for one hour while cooling on an ice-bath. The crude reaction mixture was washed with water and brine, then extracted. The separated organic layer was dried, filtered and the solvent 30 was evaporated, yielding 4.2 g of ( $\pm$ )-1,3-dioxolo[4,5-b]pyridine-2-methanol methanesulfonate (ester) (intermediate 6).

Example A.4

35 a) Under nitrogen atmosphere. 2-propen-1-ol (0.002 mol) was added dropwise to a stirred mixture of NaH 60% (0.002 mol) in DME (5ml). The mixture was stirred at room temperature for 15 minutes. A solution of 3-(methoxymethoxy)-4-chloropyridine (0.0017 mol) in DME (5 ml) was added dropwise. The resulting reaction mixture was stirred at reflux overnight. The mixture was washed with water and extracted with

ethyl acetate. The organic layer was dried, filtered and evaporated till dryness. The residue was purified by open column chromatography (eluent : hexane/ethyl acetate 3/2; CH<sub>2</sub>Cl<sub>2</sub>/2-propanone 90/10; CH<sub>2</sub>Cl<sub>2</sub>/MeOH 96/4). The product fractions were collected and the solvent was evaporated, yielding 0.18 g of 3-(methoxymethoxy)-4-(2-propenoxy)pyridine (intermediate 7).

5 b) Bromine (0.00092 mol) was added dropwise to a solution of intermediate (7) (0.00092 mol) in DCM (2 ml). The reaction mixture was stirred at room temperature for 15 minutes. The mixture was poured into a saturated NaHCO<sub>3</sub> solution with a few drops of a 10% Na<sub>2</sub>SO<sub>4</sub> solution. This mixture was extracted. The organic layer was dried over 10 Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated till dryness, yielding 0.32 g of (±)-4-(2,3-dibromopropoxy)-3-(methoxymethoxy)pyridine (intermediate 8).

c) A mixture of intermediate (8) (0.0248 mol), HCl (35.42 ml) and ethanol (40 ml) was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum. The concentrate was cooled on an ice-water bath. The mixture was 15 neutralized with a saturated NaHCO<sub>3</sub> solution and extracted with ethyl acetate. The organic layer was dried, filtered and evaporated till dryness. The residue was purified by open column chromatography (eluent: CH<sub>2</sub>Cl<sub>2</sub>; CH<sub>2</sub>Cl<sub>2</sub>/MeOH (98/2, 96/4 and 90/10)). The pure fractions were collected and the solvent was evaporated, yielding 4.27 g of (±)-4-(2,3-dibromopropoxy)-3-pyridinol (intermediate 9).

20 d) A solution of intermediate (9) (0.0097 mol) in ethanol (50 ml) was stirred and refluxed overnight. NaHCO<sub>3</sub> (0.0097 mol) was added and the resulting reaction mixture was stirred and refluxed overnight. The solvent was evaporated. The residue was washed with water and extracted with DCM. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified by open column 25 chromatography (eluent: hexane/ethyl acetate (3/2)). The pure fractions were collected and the solvent was evaporated, yielding 1.51 g of (±)-3-(bromomethyl)-2,3-dihydro-1,4-dioxino[2,3-c]pyridine (intermediate 10).

Example A.5

30 a) A mixture of 2,2 dimethyl-1,3-propanediamine (0.22 mol) and 2-propenenitrile (0.22 mol) in ethanol (250 ml) was stirred overnight at room temperature. The solvent was evaporated. A mixture of 2,2-dimethyl-1,3-propanediamine (0.28 mol) and 2-propenenitrile (0.28 mol) in ethanol (250 ml) was stirred for one hour at room temperature. The solvent was evaporated. The residues were combined. This fraction 35 was purified by distillation, yielding 27.2 g of 3-[(3-amino-2,2-dimethylpropyl)amino]-propanenitrile (intermediate 11).

b) A mixture of intermediate (11) (0.16 mol) and 1,1'-carbonylbis-1*H*-imidazole (0.16 mol) in THF (500 ml) was stirred and refluxed overnight. The precipitate was filtered off and dried, yielding 26.7 g of hexahydro-5,5-dimethyl-2-oxo-1-pyrimidinepropanenitrile (intermediate 12, mp. 190°C).

5 c) A mixture of intermediate (12) (0.12 mol) in CH<sub>3</sub>OH/NH<sub>3</sub> (400 ml) was hydrogenated with Raney Nickel (3.0 g) as a catalyst. After uptake of hydrogen (2 equivalents), the catalyst was filtered off and the filtrate was evaporated, yielding 21.2 g of 1-(3-aminopropyl)tetrahydro-5,5-dimethyl-2(1*H*)-pyrimidinone (intermediate 13).

10

Example A.6

a) A mixture of 4-amino-1-(phenylmethyl)-4-piperidinemethanol (0.0182 mol) and 2-propenenitrile (0.0304 mol) in ethanol (80 ml) was stirred and refluxed for two days. 2-Propenenitrile (2 ml) was added. The mixture was stirred and refluxed for 5 hours.

15 2-Propenenitrile (2 ml) was added again. The mixture was stirred and refluxed overnight. The solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH<sub>2</sub>Cl<sub>2</sub>/(CH<sub>3</sub>OH/NH<sub>3</sub>) 95/5). The desired fractions were collected and the solvent was evaporated, yielding 3-[[4-(hydroxymethyl)-1-(phenylmethyl)-4-piperidinyl]amino]-propanenitrile (intermediate 14).

20 b) A mixture of intermediate (14) (0.0159 mol) in methanol saturated with NH<sub>3</sub> (150 ml) was hydrogenated at 14°C with Raney nickel (1/2 spoon) as a catalyst. After uptake of hydrogen (2 equivalents), the catalyst was filtered off and the filtrate was evaporated, yielding 3.8 g of 4-[(3-aminopropyl)amino]-1-(phenylmethyl)-4-piperidinemethanol (intermediate 15).

25 c) 1,1'-Carbonylbis-1*H*-imidazole (0.0149 mol) was added to a mixture of intermediate (15) (0.0137 mol) in THF (40 ml). The mixture was stirred at room temperature overnight. The precipitate was filtered off, crystallized from ACN, filtered off, washed with ACN and DIPE and then dried, yielding 2.05 g of tetrahydro-1-[4-(hydroxy-methyl)-1-(phenylmethyl)-4-piperidinyl]-2(1*H*)-pyrimidinone (intermediate 16, mp. 210°C).

30 d) A mixture of intermediate (16) (0.0059 mol) in methanol (100 ml) was hydrogenated with palladium on carbon (1 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off, the filtrate was evaporated and crystallized from ACN, yielding 0.6 g of tetrahydro-1-[4-(hydroxymethyl)-4-piperidinyl]-2(1*H*)-pyrimidinone (intermediate 17, mp. 162°C).

35

Example A.7

A reaction solution of 1-(2-propenyl)-2,4-imidazolidinedione (0.036 mol) and 3-chlorobenzenecarboperoxoic acid (0.043 mol, 70.75%) in DCM (25 ml) was stirred for 2 hours at room temperature. An aqueous solution of bisulfite was added and the 5 mixture was stirred for 10 minutes.  $\text{Na}_2\text{CO}_3$  was added and this mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated, yielding 5 g of  $(\pm)$ -1-(oxiranylmethyl)-2,4-imidazolidinedione (intermediate 18).

Example A.8

10 a) Reaction was carried out under nitrogen flow. A mixture of 2-chloro-3-pyridinol hydrochloride (1:1) (1.760 mol) in DMF (1000 ml) was added dropwise in 30 minutes to a mixture of NaH 60% (1.934 mol) in DMF (1200 ml) (temperature below 27°C). The reaction mixture was stirred for 30 minutes. (Chloromethyl)-oxirane (3.530 mol) in DMF (1200 ml) was added dropwise over 30 minutes. The reaction mixture was stirred 15 for 9 hours at 60 °C. The mixture was cooled. Water was added dropwise on an ice bath. The mixture was extracted with DCM. The organic layer was dried, filtered and the solvent was evaporated. Petroleum ether was added to the residue, then decanted (3 times). This fraction was combined with analogously obtained fractions, then purified by HPLC over silica gel (eluent: hexane/ethyl acetate (50/50)). The desired fractions were collected and the solvent was evaporated, yielding 635 g of 2-chloro-3-(oxiranylmethoxy)-pyridine (intermediate 19).

20 b) A mixture of THF (915 ml), benzenemethanol (2.96 mol) and NaOH (2.36 mol) was stirred at room temperature for 30 minutes (cooling was required to keep the temperature below 25°C). Intermediate (19) (1.97 mol) was added. The reaction mixture was stirred at room temperature for 4 days. Water was added dropwise (cooling required) and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered and the solvent was evaporated. The residue was combined with analogously obtained fraction, then purified by HPLC over silica gel (eluent : hexane/ethyl acetate (60/40)). The desired fractions were collected and the solvent was evaporated, yielding 38% of 1-[(2-chloro-3-pyridinyl)oxy]-3-[(3Z)-3,5-hexadienyloxy]-2-propanol (intermediate 20).

25 c) A mixture of intermediate (20) (0.034 mol) and Lawesson's Reagent (0.051 mol) in toluene (750 ml) was stirred and refluxed for 16 hours. The solvent was evaporated and the residue was purified by short open column chromatography over silica gel (eluent:  $\text{CH}_2\text{Cl}_2$ /2-propanone (100/0; 90/10)). The desired fractions were collected and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: hexane/2-propanone (95/5; 90/10)). The desired fractions were 30 35

collected and the solvent was evaporated, yielding 2.3 g of 2,3-dihydro-3-[(phenylmethoxy)methyl]-[1,4]oxathiino[3,2-*b*]pyridine (intermediate 21).

d) A mixture of intermediate (21) (0.00732 mol) and  $\text{FeCl}_3$  (2.37 g) in DCM (100 ml) was stirred at room temperature for 16 hours.  $\text{FeCl}_3$  (2.37 g) was added and the mixture was stirred for 16 hours more. The reaction mixture was basified with  $\text{NH}_4\text{OH}$  (saturated) and filtered through Celite. The organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by short column chromatography over silica gel (eluent:  $\text{CH}_2\text{Cl}_2$ /2-propanone (95/5)). The desired fractions were collected and the solvent was evaporated, yielding 0.93 g of 2,3-dihydro-[1,4]oxathiino[3,2-*b*]pyridine-3-methanol (intermediate 22).

10 e) Methanesulfonyl chloride (0.0076 mol) was added slowly to a mixture of intermediate (22) (0.0051 mol) and triethylamine (0.0102 mol) in DCM (50 ml) at 0°C. The mixture was stirred at 0°C for 2 hours. Water was added. The organic layer was dried, filtered, and the solvent was evaporated, yielding 1.16 g of 2,3-dihydro-[1,4]oxathiino[3,2-*b*]pyridine-3-methanol, methanesulfonate (ester) (intermediate 23).

Example A.9

a) A mixture of  $\text{NaH}$  60% (0.051 mol) in THF (20 ml) was stirred at 0°C. A solution of 3-hydroxy-2-pyridinecarboxaldehyde (0.034 mol) in THF (75 ml) was added dropwise at 0°C. The reaction mixture was stirred for one hour at room temperature. A solution of 2-(diethoxyphosphinyl)-2-propenoic acid, ethyl ester (0.041 mol) in THF (75 ml) was added portionwise at 0°C. The reaction mixture was stirred for 24 hours at room temperature, then stirred and refluxed for 4 hours, then stirred for 24 hours at room temperature. A 10% aqueous  $\text{NH}_4\text{Cl}$  solution was added and the mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by short open column chromatography over silica gel. The desired fractions were collected and the solvent was evaporated, yielding 0.56 g of 2*H*-pyrano[3,2-*b*]pyridine-3-carboxylic acid, ethyl ester (intermediate 24).

20 b) A solution of intermediate (24) (0.0032 mol) in methanol (dry) (2 ml) and THF (dry) (16 ml) was stirred at 0°C.  $\text{NaBH}_4$  (0.0128 mol) was added portionwise at 0°C. The reaction mixture was stirred for 5 hours at room temperature. A 10%  $\text{NH}_4\text{Cl}$  solution was added and this mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated, yielding 0.45 g of 2*H*-pyrano[3,2-*b*]pyridine-3-methanol (intermediate 25).

25 c) A mixture of intermediate (25) (0.0027 mol) in methanol (20 ml) was hydrogenated for 24 hours at room temperature with palladium-on-carbon (0.04 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was

evaporated, yielding 0.35 g of 3,4-dihydro-2*H*-pyrano[3,2-*b*]pyridine-3-methanol (intermediate 26).

5 d) A solution of intermediate (26) (0.002 mol) in DCM (10 ml) was stirred at 0°C. Triethylamine (0.0024 mol) and methanesulfonyl chloride (0.0024 mol) were added at 0°C and the resulting reaction mixture was stirred for 3 hours at room temperature. A saturated aqueous NaHCO<sub>3</sub> solution was added. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 0.49 g of 3,4-dihydro-2*H*-pyrano[3,2-*b*]pyridine-3-methanol, methanesulfonate (ester) (intermediate 27).

10 Example A.10

a) To a solution of 2-chloro-3-pyridinamine (0.0465 mol) in THF (45ml) at -78°C under N<sub>2</sub> flow, lithium diisopropylamine (0.0513 mol, 2 M) was added dropwise. The mixture was allowed to warm to 0°C and was stirred for 1 hour and then cooled to -78°C. Then iodomethane (0.0582 mol) was added and the reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. A saturated NH<sub>4</sub>Cl-solution was added and the mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 80/20). The product fractions were collected and the solvent was evaporated, yielding 5.91 g of 2-chloro-*N*-methyl-3-pyridinamine (intermediate 28).

15 b) To a solution of intermediate (28) (0.031 mol) in THF (50 ml) under nitrogen flow at -78°C, lithium diisopropylamine (0.062 mol, 2 M) was slowly added. The reaction mixture was allowed to warm to 0°C and was stirred for 1 hour. After cooling again to -78°C, a solution of [(phenylmethoxy)methyl]-oxirane (0.034 mol) in THF (40 ml) was added and the mixture was allowed to warm to room temperature and was stirred for 16 hours. A saturated NH<sub>4</sub>Cl-solution was added and the mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 50/50). The product fractions were collected and the solvent was evaporated, yielding 7.18 g of 1-[(2-chloro-3-pyridinyl)methylamino]-3-(phenylmethoxy)- 2-propanol (intermediate 29).

20 c) To a suspension of NaH 60% (0.081 mol) in DME (250 ml), a solution of intermediate (29) (0.023 mol) in DME (250 ml) was added dropwise. The reaction mixture was stirred and refluxed for 16 hours. After cooling, the mixture was taken up in H<sub>2</sub>O/ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 95/5). The desired fractions were collected and the

solvent was evaporated, yielding 5.82 g of 1-[(2-chloro-3-pyridinyl)methylamino]-3-(phenylmethoxy)-2-propanol (intermediate 30).

d) A mixture of intermediate (30) (0.018 mol) and  $\text{FeCl}_3$  (0.036 mol) in DCM (500ml) was stirred at room temperature for 16 hours. Then  $\text{FeCl}_3$  (0.018 mol) was added and  
5 the mixture was stirred for 6 hours more. Extra  $\text{FeCl}_3$  (0.018 mol) was added again and the mixture was stirred for 16 hours. The reaction mixture was basified with a saturated  $\text{NH}_4\text{Cl}$ -solution and the formed precipitate was filtered over dicalite. The separated organic layer was extracted with a saturated  $\text{NH}_4\text{Cl}$ -solution, dried, filtered and the solvent was evaporated. The residue was purified by short open column  
10 chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2$ /(MeOH/ $\text{NH}_3$ ) 95/5). The product fractions were collected and the solvent was evaporated. The residue was purified again by short open column chromatography over silica gel (eluent : ethyl acetate/(MeOH/ $\text{NH}_3$ ) 98/2;95/5). The desired fractions were collected and the solvent was evaporated, yielding 2.1 g of 2,3-dihydro-1-methyl-1*H*-pyrido[2,3-*b*][1,4]oxazine-3-methanol (intermediate 31).  
15 e) To a solution of intermediate (31) (0.0111 mol) and triethylamine (0.0222 mol) in DCM (200 ml) at 0°C, methanesulfonyl chloride (0.0166 mol) was added dropwise. The reaction mixture was stirred at 0°C for 1 hour. Then water was added. The separated organic layer was extracted with brine, dried, filtered and the solvent was  
20 evaporated, yielding 2.85 g of 2,3-dihydro-1-methyl-1*H*-pyrido[2,3-*b*][1,4]oxazine-3-methanol, methanesulfonate (ester) (intermediate 32).

#### Example A.11

a) A solution of 3-chloro-benzenecarboxylic acid (0.087 mol) in trichloromethane (125 ml) was added dropwise to a solution of 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridine-3-methanol methanesulfonate ester (0.0217 mol) in trichloromethane (125 ml) and it was stirred at room temperature overnight. 50 ml of methanol and 12.47g of  $\text{K}_2\text{CO}_3$  were added and the mixture was stirred for 30 minutes. Then, it was filtered off and the solid was washed with a mixture of DCM in methanol (90/10). The filtrate was evaporated till dryness and the residue was purified by open column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2$ /(MeOH/ $\text{NH}_3$ ) 96/4, 95/5 and 90/10). The product fractions were collected and the solvent was evaporated, yielding 3.62 g of 2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol, methanesulfonate (ester) (intermediate 33).  
30 b) A mixture of intermediate (33) (0.0138 mol) and phosphorus oxychloride (0.069 mol) was stirred for 3 hours at 100°C. The crude reaction mixture was evaporated till dryness. The cooled residue was carefully treated with water and then it was neutralized with  $\text{Na}_2\text{CO}_3$ . The mixture was extracted with DCM. The separated  
35

organic layer was dried, filtered and evaporated till dryness, yielding 3.17 g of 6-chloro-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol, methanesulfonate (ester) (intermediate 34).

5 Example A.12

a) Bromine (0.009 mol) was added dropwise to a solution of 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridine-3-methanol (0.009 mol) in DCM (100 ml) and Na<sub>2</sub>CO<sub>3</sub> saturated solution (50 ml), stirred at room temperature. The reaction mixture was stirred for 16 hours at room temperature. More bromine (0.009 mol) was added and the 10 reaction mixture was stirred for 3 more days at room temperature. A few drops of Na<sub>2</sub>SO<sub>3</sub> were added and the mixture was stirred for 15 minutes. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by short open column chromatography over silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 100/0; 98/2). The desired fractions were collected and the solvent was evaporated, yielding 0.9 g of 7-bromo-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol (intermediate 35).

b) Methanesulfonyl chloride (0.0054 mol) was added dropwise to a mixture of intermediate (35) (0.0036 mol) and triethylamine (0.0072 mol) in DCM (50 ml), stirred at 0°C. The reaction mixture was stirred for 30 minutes at 0°C, and then it was extracted with water. The organic layer was separated, dried, filtered and the solvent 20 was evaporated, yielding 1.07 g of 7-bromo-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol, methanesulfonate (ester) (intermediate 36).

Example A.13

a) Chloro(1,1-dimethylethyl)dimethyl-silane (0.020 mol) was added dropwise to a 25 solution of intermediate (38) (0.010 mol) and 1*H*-imidazole (0.020 mol) in DMF (100 ml) and the reaction mixture was stirred for 16 hours at room temperature. The solvent was evaporated. The residue was taken up into water/ethyl acetate. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent: hexane/ethyl acetate 90/100). The desired fractions were collected and the solvent was evaporated, 30 yielding 2.4 g of 7-bromo-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine (intermediate 37).

b) Reaction under nitrogen atmosphere. A solution of intermediate (37) (0.00194 mol) in THF was cooled to -78°C. BuLi (0.00214 mol, 2.5M) was added dropwise and the 35 mixture was stirred for 75 minutes at -78°C. Then, iodomethane (0.00214 mol) was added and the reaction mixture was stirred for 45 minutes. A saturated aqueous NH<sub>4</sub>Cl solution was added and the mixture was allowed to warm to room temperature. This

mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by flash column chromatography over silica gel (eluent: hexane/ethyl acetate 80/20). The desired fractions were collected and the solvent was evaporated, yielding 0.24 g of 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-7-methyl-[1,4]dioxino[2,3-*b*]pyridine (intermediate 38).

5 c) Reaction under nitrogen atmosphere. TBAF, 1M/THF (0.00122 mol) was added to a solution of intermediate (41) (0.00081 mol) in THF anhydrous (5 ml), stirred at room temperature. The reaction mixture was stirred for 16 hours. Water was added. This mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent evaporated, yielding 0.147 g of 2,3-dihydro-7-methyl-[1,4]dioxino-[2,3-*b*]pyridine-3-methanol (intermediate 39).

10 d) Methanesulfonyl chloride (0.00103 mol) was added to a mixture of intermediate (39) (0.00081 mol) and triethylamine (0.0019 mol) in DCM, stirred at 0°C. The reaction mixture was stirred for 30 minutes at 0°C. Water was added. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 0.208 g of 2,3-dihydro-7-methyl-[1,4]dioxino[2,3-*b*]pyridine-3-methanol methanesulfonate (ester) (intermediate (40)).

#### Example A.14

20 a) To a solution of intermediate (2-a) (0.03 mol) in DCM (50 ml) and Na<sub>2</sub>CO<sub>3</sub> saturated (50 ml), bromine (0.09 mol) was added dropwise and the reaction mixture was stirred for 16 hours at room temperature. Then a Na<sub>2</sub>SO<sub>3</sub>-solution (10%) was added and the mixture was stirred for 5 minutes at room temperature and then neutralized with a saturated Na<sub>2</sub>CO<sub>3</sub>-solution. The aqueous layer was extracted with DCM and the separated combined organic layers were dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : CH<sub>2</sub>Cl<sub>2</sub>/(MeOH/NH<sub>3</sub> saturated) 95/5). The desired fractions were collected and the solvent was evaporated. The residue was purified by high-performance liquid chromatography over silica gel (eluent : CH<sub>2</sub>Cl<sub>2</sub>/(MeOH/NH<sub>3</sub> saturated) 97/3). The product fractions were collected and the solvent was evaporated, yielding 2.7 g of (S)-7-bromo-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol (intermediate 41) and 0.26 g of 8-bromo-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol (intermediate 42).

25 b) To a mixture of intermediate (42) (0.0014 mol) and triethylamine (0.0028 mol) in DCM (5 ml), methanesulfonyl chloride (0.0021 mol) was slowly added at room temperature. The reaction mixture was stirred for 16 hours and was then extracted with water. The separated organic layer was dried, filtered and the solvent was evaporated,

yielding 0.42 g of (S)-8-bromo-2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridine-3-methanol methanesulfonate (ester) (intermediate (43)).

Example A.15

5 a) A solution of diazenedicarboxylic acid diethyl ester (0.1572 mol) in THF (163ml) was added dropwise to a mixture of 4-chloro-3-pyridinol (0.1429 mol), 2-propen-1-ol (0.1572 mol) and triphenyl-phosphine (0.1572 mol) in THF (276 ml), that was cooled with an ice-water bath and under nitrogen flow. The formed mixture was stirred on the ice-water bath for 15 minutes and at room temperature overnight. The mixture was

10 concentrated under vacuum and the residue was washed with a saturated  $\text{Na}_2\text{CO}_3$ -solution. The mixture was extracted with DCM and the separated organic layer was dried, filtered and the solvent was evaporated until dry. The residue was treated with DIPE and the formed solid was filtered off and discarded. The filtrate was evaporated until dry and the residue was treated with diethyl ether and the formed solid was filtered

15 off and discarded again. The filtrate was evaporated until dry and the residue was purified by open column chromatography over silica gel (eluent : DCM/2-propanone 99/1;98/2). The product fractions were collected and the solvent was evaporated, yielding 7.9 g of 4-chloro-3-(2-propenyl)-pyridine (intermediate (44)).

b) To a mixture of  $\text{NaH}$  60% (0.11 mol) in DME (170 ml), under nitrogen flow,

20 benzenemethanol (0.0698 mol) was added dropwise and the mixture was stirred at room temperature for 30 minutes. Then a solution of intermediate (44) (0.046 mol) in DME (170 ml) was added dropwise and the resulting mixture was stirred and refluxed overnight. The cooled reaction mixture was washed with water and extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated

25 until dry. The residue was purified by open column chromatography over silica gel (eluent: DCM/2-propanone/MeOH 100/0/0;96/4/0;96/0/4;90/0/10). The product fractions were collected and the solvent was evaporated, yielding 6.2 g of 4-(phenylmethoxy)-3-(2-propenyl)-pyridine (intermediate 45).

c) To a solution of intermediate (45) (0.0256 mol) in DCM (64 ml), bromine (0.0256 mol) was added dropwise and the mixture was stirred at room temperature for

30 30 minutes. The reaction mixture was washed with a saturated  $\text{NaHCO}_3$ -solution and a few drops of  $\text{Na}_2\text{SO}_3$ -solution 10% and it was extracted. The separated organic layer was dried, filtered and the solvent was evaporated until dry. The residue was purified by open column chromatography (eluent : DCM/MeOH 100/0,99/1,98/2). The product fractions were collected and the solvent was evaporated, yielding 6.68 g of 3-(2,3-dibromopropoxy)-4-(phenylmethoxy)-pyridine (intermediate 46).

d) To a solution of intermediate (46) (0.0166 mol) in DCM (270 ml),  $\text{FeCl}_3$  (0.033 mol) was added portionwise and the mixture was stirred at room temperature overnight. The reaction mixture was treated with a saturated  $\text{NH}_4\text{Cl}$ -solution and with a diluted solution of potassium sodium tartrate and then it was filtered off over celite. The solvent was evaporated until dry and the residue was treated with methanol and then filtered off. The filtrate was evaporated until dry and the residue was treated with 2,3-dihydroxy butaenedioic acid, monopotassium monosodium salt (1 g) in ethanol and refluxed for 18 hours. The cooled reaction mixture was filtered off over celite and the filtrate was evaporated until dry. The residue was washed with water and extracted with DCM. The separated organic layer was dried, filtered and the solvent was evaporated until dry. The residue was purified by flash column chromatography over silica gel (eluent : ethyl acetate/(MeOH/NH<sub>3</sub>) 96/4). The product fractions were collected and the solvent was evaporated, yielding 0.52 g of 2-(bromomethyl)-2,3-dihydro-[1,4]dioxino-[2,3-*c*]pyridine (intermediate 47).

15

Example A.16

a) 5-Bromo-pyrimidine (0.063 mol) was slowly added to 2-propen-1-ol (4.03 mol) at 0°C and this mixture was stirred at room temperature for 1 hour. Then NaH 60% (0.126 mol) was added and the reaction mixture was stirred and refluxed for 48 hours. Water was added and the mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 50/50). The desired fractions were collected and the solvent was evaporated, yielding 2.3 g of 5-(2-propenyoxy)-pyrimidine (intermediate 48).

b) To a solution of intermediate (48) (0.0169 mol) in DCM (250 ml), bromine (0.0186 mol) was slowly added and the reaction mixture was stirred at room temperature for 1 hour. The solvent was extracted with a saturated  $\text{Na}_2\text{CO}_3$ -solution and a few drops of a  $\text{Na}_2\text{SO}_3$ -solution (10%). The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 66/33;50/50). The desired fractions were collected and the solvent was evaporated, yielding 3.85 g of 3-(2,3-dibromopropoxy)-pyridine (intermediate 49).

c) To a solution of intermediate (49) (0.0123 mol) and  $\text{H}_2\text{SO}_4$  (0.0135 mol) in water (5 ml),  $\text{CH}_3\text{CO}_3\text{H}$  35% (0.0246 mol) was added dropwise and the reaction mixture was stirred at room temperature for 16 hours. The mixture was extracted with ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent :

ethyl acetate/(MeOH/NH<sub>3</sub>) 95/5). The desired fractions were collected and the solvent was evaporated, yielding 2.83 g of 5-(2,3-dibromopropoxy)- 4(3H)-pyrimidinone (intermediate 50).

5 d) A mixture of intermediate (50) (0.0091 mol) and NaHCO<sub>3</sub> (0.0113 mol) in ethanol (100 ml) was stirred and refluxed for 16 hours. The reaction mixture was allowed to cool to room temperature and the solvent was evaporated. The residue was taken up in water and ethyl acetate. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : hexane/ethyl acetate 66/33;50/50). The desired fractions were  
10 collected and the solvent was evaporated, yielding 1.1 g of 7-(bromomethyl)-6,7-dihydro-[1,4]dioxino[2,3-*d*]pyrimidine (intermediate 51).

Example A.17

a) Reaction under an argon flow. A mixture of 1-amino-3-dibenzylaminopropane (0.195 mol) in ethanol (225 ml) was stirred at room temperature. Ethyl propenoate (0.2 mol) was poured into the mixture and the reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH<sub>2</sub>Cl<sub>2</sub>/hexane/CH<sub>3</sub>OH 50/45/5). The desired fractions were collected and the solvent was evaporated, yielding 27 g of *N*-[3-[bis(phenylmethyl)amino]propyl]-  $\beta$ -alanine, ethyl ester (intermediate 52).  
15 b) Intermediate (52) was stirred in ethanol (150 ml). The mixture was acidified with HCl/2-propanol ( $\pm$  60 ml) + water (2 ml). The mixture was stirred for 15 minutes. The solvent was evaporated at 60°C. Ethanol was added to the residue. The solvent was evaporated. A mixture of methanol in water (70:30; 200 ml) was added to the residue  
20 and the mixture was stirred, then warmed slightly until complete dissolution. The acidic solution was added dropwise (over 30 minutes, under argon) to a solution of KOCN (0.100 mol) in a mixture of methanol in water (70:30; 100 ml), stirred at room temperature pH went from  $\pm$  8 to  $\pm$  6). The reaction mixture was stirred for 19 hours at room temperature. More KOCN (0.32 g) was added and the reaction mixture was  
25 stirred for 90 minutes at room temperature. More KOCN (0.9 g) was added and the reaction mixture was stirred for 75 minutes at room temperature, then for 6 days at 95°C. The reaction mixture was cooled. Concentrated HCl (20 ml) was added dropwise. The reaction mixture was stirred for 2 hours at 95°C, then stood overnight at room temperature. The precipitate was filtered off, and the filtrate was stirred and  
30 cooled for 3 hours on an ice-bath. The resulting precipitate was filtered off and dried, yielding 19.6 g of 1-[3-[bis(phenylmethyl)amino]propyl]dihydro-2,4(1H,3H)-pyrimidinedione (intermediate 53).  
35

c) A mixture of intermediate (53) (0.010 mol) in methanol (150 ml) was hydrogenated at 50°C with palladium-on-carbon (10%, 1 g) as a catalyst. After uptake of hydrogen (2 equivalents), the catalyst was filtered off and the filtrate was evaporated. Toluene was added and azeotroped on the rotary evaporator. The residue was dried over the 5 weekend under a gentle stream of nitrogen. Toluene was added and azeotroped on the rotary evaporator. The residue was stirred in DCM (50 ml). NaOCH<sub>3</sub> (0.504 g) was added and the reaction mixture was stirred for one hour under nitrogen. More methanol (25 ml) was added and the mixture was stirred for 30 minutes. The precipitate was filtered off and the filtrate was evaporated in vacuo, yielding 1.54 g of 1-(3-10 aminopropyl)dihydro-2,4(1H,3H)-pyrimidinedione (intermediate 54).

B. Preparation of the final compounds

Example B.1

A mixture of intermediate (1) (0.00815 mol), 1-(3-aminopropyl)tetrahydro-2(1H)-15 pyrimidinone (0.00815 mol) and CaO (0.022 mol) in (26.5 ml) was stirred at 100°C overnight in a Parr apparatus. The excess of CaO was filtered off. The filtrate was evaporated till dryness. The residue was purified by open column chromatography over silica gel (eluent 1: CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 90/10 and eluent 2: CH<sub>2</sub>Cl<sub>2</sub>/(CH<sub>3</sub>OH/NH<sub>3</sub>) 96/4). The pure fractions were collected and the solvent was evaporated. The residue was 20 purified again by HPLC over silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>/(CH<sub>3</sub>OH/NH<sub>3</sub>) 93/7). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.88 g of (±)-1-[3-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]amino]propyl]tetrahydro-2(1H)pyrimidinone (compound 1).

25

Example B.2

A mixture of intermediate (6) (0.0092 mol) and intermediate (13) (0.0183 mol) was stirred for 2 hours at 100°C. The crude reaction mixture was purified by open column chromatography over silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 90/10). The desired fractions 30 were collected and the solvent was evaporated. The residue was washed with DIPE, then dried, yielding 1.48 g of (±)-1-[3-[(1,3-dioxolo[4,5-b]pyridin-2-ylmethyl)amino]propyl]tetrahydro-5,5-dimethyl-2(1H)-pyrimidinone (compound 10).

Example B.3

35 A mixture of 2-(bromomethyl)-3,4-dihydro-2H-pyrano[2,3-b]pyridine (0.007 mol) and 1-(3-aminopropyl)tetrahydro-2(1H)-pyrimidinone (0.014 mol) was stirred for 2 hours at 100°C. The crude reaction mixture was treated with DCM and the resulting solid was filtered off and discarded. The filtrate was evaporated and the residue was purified by

open column chromatography over silica gel (eluent:  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  84/16,  $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$  90/10). The purest fractions were collected and the solvent was evaporated. The residue was dissolved in ethanol and converted into the ethanedioic acid salt (1:1), then filtered off and recrystallized from ethanol, yielding 0.45 g of ( $\pm$ )-1-[3-[(3,4-dihydro-2H-pyrano[2,3-b]pyridin-2-yl)methyl]amino]propyl]tetrahydro-2(1H)-pyrimidinone ethanedioate (1:1) (compound 9).

Example B.4

10 A mixture of 2,3-dihydro-*N*-(phenylmethyl)-1,4-dioxino[2,3-b]pyridine-3-methanamine (0.0059 mol) and intermediate (18) (0.00497 mol) in methanol (30 ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/2$ -propanone 96/4, 90/10 and 80/20), then  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  96/4 and 90/10). The product fractions were collected and the solvent was evaporated, yielding 1.29 g of ( $\pm$ )-1-[3-[(2,3-dihydro-1,4-dioxino-[2,3-b]pyridin-3-yl)methyl](phenylmethyl)amino]-2-hydroxypropyl]-2,4-imidazolidinedione (compound 12).

Example B.5

20 A solution of compound (12) (0.0031 mol) in methanol (40 ml) was hydrogenated in Parr apparatus at 50°C with palladium-on-carbon (10%, 0.13 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by HPLC over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$  gradient from 90/10 to 92.5/7.5). The product fractions were collected and the solvent was evaporated, yielding 0.3 g of 1-[3-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]amino]-2-hydroxypropyl]-2,4-imidazolidinedione (compound 13).

Example B.6

30 Potassium hydroxide (0.0022 mol) in ethanol was added to compound (44) (0.0012 mol) in ethanol. The reaction mixture was stirred for 4 hours at 50°C, then overnight at room temperature. The solvent was evaporated. The residue was purified by HPLC over RP BDS (Hyperprep C18 (100 Å, 8 µm; eluent:  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  (0 min) 100/0, (24 min) 63/37, (24.01-32 min) 0/100). The product fractions were collected and the solvent was evaporated, yielding 0.050 g of compound (50).

35

Example B.7

Reaction under nitrogen atmosphere. Compound (R268652) (0.0037 mol) was stirred in THF (120 ml), and cooled on an ice-water bath. Lithiumborohydride (0.0074 mol; 3.7

ml of a 2 M solution in THF) was added and the reaction mixture was stirred for one hour at room temperature. The mixture was stirred and refluxed for 5 hours, then stirred over the weekend at room temperature, then stirred and refluxed overnight, and finally cooled to room temperature. More lithiumborohydride (0.0074 mol) was added 5 and the reaction mixture was stirred and refluxed overnight, then cooled to room temperature. Water was added. The mixture was alkalized with 50% NaOH, and then the organic solvent (THF) was evaporated. The residue was purified by column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  95/5). The desired fractions were collected and the solvent was evaporated. The residue was taken up into a small 10 amount of ACN, warmed until complete dissolution, then cooled on an ice-bath and the resulting precipitate was filtered off, washed and dried, yielding 0.7 g of compound (51).

Example B.8

15 A solution of meta-chloroperbenzoic acid (0.0027 mol) in chloroform (34 ml) was added dropwise to a solution of compound (14) (0.0024 mol) in chloroform (8 ml) that was cooled to -50°C. The mixture was stirred for 1 hour at a temperature -50°C to -20°C. Then methanol and  $\text{K}_2\text{CO}_3$  were added. The formed mixture was stirred at room temperature for 30 minutes and then it was filtered off. The solid was washed with 20  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (80/20) and the filtrate was evaporated till dryness. The mixture was purified by flash column chromatography with  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/(\text{CH}_3\text{OH}/\text{NH}_3)$  (80/20/0; 85/0/15;80/0/20). The product fractions were collected and washed with DCM. The solvent was filtered and evaporated, yielding 0.44g of compound (40).

25 Example B.9

Compound (60) (0.0091 mol) was purified and separated by high performance liquid chromatography over Chiralpak AD (eluent :  $\text{C}_2\text{H}_5\text{OH}/\text{CH}_3\text{CN}$  (64/36)). The product fractions were collected, the solvent was evaporated, and each residue was dissolved in ethanol and converted into the ethanedioic acid salt (1:1). Yielding 0.7 g 30 of compound (27),  $[\alpha]_D^{20} = -42.50^\circ$  (c = 25.06 mg/ 5 ml in  $\text{CH}_3\text{OH}$ ), mp. 212°C; and 0.9 g of compound (28) ,  $[\alpha]_D^{20} = +42.77^\circ$  (c = 25.72 mg/ 5 ml in  $\text{CH}_3\text{OH}$ ), mp. 216°C.

Example B.10

A mixture of intermediate (3) (0.04 mol), 1-(4-piperidinyl)-2-imidazolidinone 35 (0.05 mol) and  $\text{NaHCO}_3$  (0.09 mol) in 1,4-dioxane (300 ml) was stirred and refluxed for 60 hours. The solvent was evaporated. The residue was partitioned between water and DCM. The separated organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent :

$\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  95/5). The desired fractions were collected and the solvent was evaporated. The residue was solidified in DIPE, filtered off and dried, yielding 6.13 g (48.3%) of compound (19) (mp. 132°C;  $[\alpha]_D^{20} = -41.70^\circ$  (c = 24.34 mg/5 ml in methanol).

5

Example B.11

A mixture of intermediate (54) (0.058 mol) in dioxane (400 ml) was stirred. A mixture of intermediate (3) (0.029 mol) and CaO (2.4 g) was added. The reaction mixture was stirred at 140°C for 16 hours. The solvent was evaporated. DCM and water was added to the residue. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by high-performance liquid chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$  90/10). The product fractions were collected and the solvent was evaporated. The residue was dissolved in ethanol and converted into the ethanedioic acid salt (1:1). The formed precipitate was filtered off and dried, yielding 1.5 g of (S)-1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]amino]propyl]dihydro-2,4(1*H*,3*H*)-pyrimidinedione (compound 25), mp.186;  $[\alpha]_D^{20} = -37.46^\circ$ , (c = 26.56 mg/5 ml DMF).

Example B.12

20 a) A mixture of intermediate (3) (0.041 mol), benzylamine (0.041 mol) and  $\text{NaHCO}_3$  (0.11 mol) in dioxane (100 ml) was stirred and refluxed for 48 hours. The solvent was evaporated. The residue was taken up in water and DCM. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  95/5). The desired fractions were collected, the solvent was evaporated, yielding (S)-2,3-dihydro-*N*-(phenylmethyl)-[1,4]dioxino[2,3-*b*]pyridine-3-methanamine (intermediate 55).

25 b) Intermediate (55) (0.0195 mol) was dissolved in ethanol (50 ml). 2-Propenenitrile (0.02 mol) was added and the reaction mixture was stirred and refluxed overnight. Additional 2-propenenitrile (0.02 mol) was added and the reaction mixture was stirred and refluxed for 2 hours. Additional 2-propenenitrile (0.02 mol) was added and the reaction mixture was stirred and refluxed for 6 hours. Additional 2-propenenitrile (0.02 mol) was added and the reaction mixture was stirred and refluxed overnight. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  97/3). The product fractions were collected and the solvent was evaporated, yielding 6.0 g of (S)-3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl](phenylmethyl)amino]-propanenitrile (intermediate 56).

c) A mixture of intermediate (56) (0.0195 mol) in methanol saturated with  $\text{NH}_3$  (400 ml) was hydrogenated with Raney nickel (1 g) as a catalyst. After uptake of hydrogen (2 equivalents), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$  90/10). The product fractions were collected and the solvent was evaporated, yielding 2.7 g of (S)- $N^1$ -[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]- $N^1$ -(phenylmethyl)-1,3-propanediamine (intermediate 57).


d) Ethyl monobromoacetate (0.0032 mol) was dissolved in THF (30 ml). This solution was added dropwise and slowly to a mixture of intermediate (57) (0.0032 mol) and triethylamine (0.0048 mol) in THF (50 ml). The reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The residue was partitioned between water and DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent :  $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$  99/1). The desired fractions were collected and the solvent was evaporated, yielding 0.8 g of (S)-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl](phenylmethyl)amino]propyl]amino]- acetic acid, ethyl ester (intermediate 58).

e) A mixture of intermediate (59) (0.002 mol) in dioxane (7.3 ml) and THF (2.4 ml) was stirred at room temperature. Trimethylsilyl isocyanate (0.0023 mol) was added and the reaction mixture was stirred and refluxed for one hour. The solvent was evaporated. The residue was dissolved in HCl (6 N; 6.2 ml), then stirred and refluxed for one hour. The reaction mixture was cooled, poured out into  $\text{NH}_4\text{OH}$ /ice, and extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated, yielding 0.4 g of (S)-1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]- (phenylmethyl)amino]propyl]- 2,4-imidazolidinedione (intermediate 60).

f) A mixture of intermediate (61) (0.001 mol) in methanol (50 ml) was hydrogenated with palladium-on-carbon (0.2 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in ethanol and converted into the ethanedioic acid salt (1:1), yielding 0.3 g of compound (30), (mp. 190°C;  $[\alpha]_D^{20} = -35.99^\circ$  (c = 24.87 mg/5 ml in DMF)).

Table F-1 to F-7 list the compounds that were prepared according to one of the above Examples. The following abbreviations were used : . $\text{C}_2\text{H}_2\text{O}_4$  stands for the ethanedioate salt

Table F-1




Co. No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Q-$	Physical data (mp. in °C)
1	B.1	$-N=CH-CH=CH-$	$-(CH_2)_3-$	mp. 77.5
2	B.1	$-N=CH-CH=CH-$	$-(CH_2)_3-$	(A); $.C_2H_2O_4$ (1:1); $[\alpha]_D^{20} = +44.40^\circ$ (c = 24.66 mg/5 ml in methanol)
3	B.1	$-N=CH-CH=CH-$	$-(CH_2)_3-$	(B); $.C_2H_2O_4$ (1:1); mp. 203; $[\alpha]_D^{20} = -44.65^\circ$ (c = 24.75 mg/5 ml in methanol)
4	B.1	$-N=CH-CH=CH-$	$-CH_2-C(CH_3)_2-CH_2-$	$.C_2H_2O_4$ (1:1); mp. 164.9
5	B.1	$-CH=CH-CH=N-$	$-CH_2-C(CH_3)_2-CH_2-$	-
6	B.2	$-N=CH-CH=CH-$	$-CH_2-CO-$	$.C_2H_2O_4$ (1:1)
7	B.2	$-N=CH-CH=CH-$	$-CH_2-CH_2-CO-$	-
8	B.3	$-CH=N-CH=CH-$	$-(CH_2)_3-$	$.C_2H_2O_4$ (1:1)
25	B.11	$-N=CH-CH=CH-$	$-CH_2-CH_2-CO-$	(S); $.C_2H_2O_4$ (1:1); mp. 186; $[\alpha]_D^{20} = -37.46^\circ$ (c = 26.56 mg/5 ml DMF)
26	B.2	$-N=CH-CBr=CH-$	$-(CH_2)_3-$	$.C_2H_2O_4$ (1:1);
27	B.9	$-CH=N-CH=CH-$	$-(CH_2)_3-$	(A); $.C_2H_2O_4$ (1:1); mp. 212°C; $[\alpha]_D^{20} = -42.50^\circ$ (c = 25.06 mg/5 ml in $CH_3OH$ )
28	B.9	$-CH=N-CH=CH-$	$-(CH_2)_3-$	(B); $.C_2H_2O_4$ (1:1); mp. 216°C; $[\alpha]_D^{20} = +42.77^\circ$ (c = 25.72 mg/5 ml in $CH_3OH$ )
29	B.3	$-N=CH-N=CH-$	$-(CH_2)_3-$	$.C_2H_2O_4$ (1:1);

-37-

Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Q-$	Physical data (mp. in °C)
30	B.12	$-N=CH-CH=CH-$	$-CH_2-CO-$	(S); $.C_2H_2O_4$ (1:1); mp.190; $[\alpha]_D^{20} = -35.99^\circ$ (c = 24.87 mg/5 ml DMF)
60	B.3	$-CH=N-CH=CH-$	$-(CH_2)_3-$	-


Table F-2



Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Q-$	Physical data (mp. in °C)
9	B.2	$-N=CH-CH=CH-$	$-(CH_2)_3-$	$.C_2H_2O_4$ (1:1); mp. 195.7


5

Table F-3




Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Q-$	Physical data (mp. in °C)
10	B.2	$-N=CH-CH=CH-$	$-CH_2-C(CH_3)_2-CH_2-$	-
11	B.2	$-N=CH-CH=CH-$	$-(CH_2)_3-$	$.C_2H_2O_4$ (1:1)

10 Table F-4



Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$R^6$	$-Q-$	Physical data (mp. in °C)
12	B.4	$-N=CH-CH=CH-$	benzyl	$-CH_2-CO-$	-
13	B.5	$-N=CH-CH=CH-$	H	$-CH_2-CO-$	-

Table F-5




Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Alk^1-A-$	$-Q-$	Physical data (mp. in °C)
14	B.2	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_2-$	-
15	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	mp. 160°C
16	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	(A); mp. 160°C; $[\alpha]_D^{20} = +30.11^\circ$ (c = 23.75 mg/5 ml in methanol)
17	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	(B); mp. 165°C; $[\alpha]_D^{20} = -30.11^\circ$ (c = 9.30 mg/5 ml in methanol)
18	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_2-$	(A); mp. 132°C; $[\alpha]_D^{20} = +38.88^\circ$ (c = 24.95 mg/5 ml in methanol)
19	B.10	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_2-$	(S); mp. 132; $[\alpha]_D^{20} = -41.70^\circ$ (c = 24.34 mg/5 ml in methanol)
20	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	mp. 200°C
21	B.1	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	(A); mp. 195°C; $[\alpha]_D^{20} = +38.51^\circ$ (c = 25.97 mg/5 ml in methanol)
22	B.10	$-N=CH-CH=CH-$	$-CH_2-N$	$-(CH_2)_3-$	(S); mp. 195°C; $[\alpha]_D^{20} = -41.90^\circ$ (c = 24.82 mg/5 ml in methanol)

Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	-Alk <sup>1</sup> -A-	-Q-	Physical data (mp. in °C)
23	B.2	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-\text{CH}_2-\text{CO}-$	.C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> (1:1)
31	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	(A-trans),
32	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	(B-trans); mp. 180°C
33	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	(A-cis); mp. 150°C
34	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	(B-cis)
35	B.3	$-CH=N-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
36	B.3	$-CH=CH-N=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
37	B.2	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
38	B.2	$-N=CH-C(CH_3)=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
39	B.2	$-N=CCl-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
40	B.8	$-N(O)=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	.H <sub>2</sub> O (1:2)
41	B.3	$-N=CH-N=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	-
42	B.2	$-N=CH-CH=CBr-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	(A)
43	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	[B-[1(B),3ALPHA,4BETA]]
44	B.9	$-N=CH-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_3-$	[B-[1(B),3ALPHA,4ALPHA]]
45	B.9	$-CH=N-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	(A); mp. 206°C
46	B.9	$-CH=N-CH=CH-$	$-\text{CH}_2-N$ 	$-(\text{CH}_2)_2-$	(B); mp. 206°C

-40-

Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Alk^1-A-$	$-Q-$	Physical data (mp. in °C)
47	B.9	$-N=CH-CH=CH-$		$-(CH_2)_3-$	[A-[1(B),3ALPHA,4BETA]] mp.194
48	B.9	$-N=CH-CH=CH-$		$-(CH_2)_3-$	[A-[1(B),3ALPHA,4ALPHA]]
49	B.6	$-N=CH-CH=CH-$		$-(CH_2)_3-$	[A-[1(B),3ALPHA,4BETA]]
50	B.6	$-N=CH-CH=CH-$		$-(CH_2)_3-$	[B-[1(B),3ALPHA,4BETA]]
51	B.7	$-N=CH-CH=CH-$		$-(CH_2)_3-$	[A-[1(B),3ALPHA,4ALPHA]]


Table F-6



Co No.	Ex. No.	$-a^1=a^2-a^3=a^4-$	$-Alk^1-A-$	$-Q-$	Physical data (mp. in °C)
24	B.2	$-N=CH-CH=CH-$		$-(CH_2)_2-$	-

5

Table F-7



Co No.	Ex. No.		$-Q-$	Physical data (mp. in °C)
52	B.2		$-(CH_2)_3-$	(A); .C2H2O4

Co No.	Ex. No.		-Q-	Physical data (mp. in °C)
53	B.2		-(CH <sub>2</sub> ) <sub>3</sub> -	(B); .C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>
54	B.2		-(CH <sub>2</sub> ) <sub>2</sub> -	-
55	B.2		-(CH <sub>2</sub> ) <sub>3</sub> -	-
56	B.2		-(CH <sub>2</sub> ) <sub>2</sub> -	-
57	B.9		-(CH <sub>2</sub> ) <sub>2</sub> -	(A)
58	B.9		-(CH <sub>2</sub> ) <sub>2</sub> -	(B)
59	B.2		-(CH <sub>2</sub> ) <sub>2</sub> -	-

### C. Pharmacological examples

#### C.1. Gastric tone measured by an electronic barostat in conscious dogs

5 Gastric tone cannot be measured by manometric methods. Therefore an electronic barostat was used. This allows the study of the physiological pattern and regulation of 10 gastric tone in conscious dogs and the influence of test-compounds on this tone.

The barostat consists of an air injection system which is connected by a double-lumen 14-French polyvinyl tube to an ultrathin flaccid polyethylene bag (maximal volume: 10  $\pm 700$  ml). Variations in gastric tone were measured by recording changes in the volume of air within an intragastric bag, maintained at a constant pressure. The barostat maintains a constant pressure (preselected) within a flaccid air-filled bag introduced into the stomach, changing the volume of air within the bag by an electronic feedback system.

15 Thus, the barostat measures gastric motor activity (contraction or relaxation) as changes in intragastric volume (decrease or increase resp.) at a constant intragastric pressure.

-42-

The barostat consists of a strain gauge linked by an electronic relay to an air injection-aspiration system. Both the strain gauge and the injection system are connected by means of double-lumen polyvinyl tube to an ultrathin polyethylene bag. A dial in the barostat allows selection of the pressure level to be maintained within the intragastric bag.

5 Female beagle dogs, weighing 7-17 kg, were trained to stand quietly in Pavlov frames. They were implanted with a gastric cannula under general anaesthesia and aseptic precautions. After a median laparotomy, an incision was made through the gastric wall 10 in longitudinal direction between the greater and the lesser curve, 2 cm above the nerves of Latarjet. The cannula was secured to the gastric wall by means of a double purse string suture and brought out via a stub wound at the left quadrant of the hypochondrium. Dogs were allowed a recovery period of two weeks.

15 At the beginning of the experiment, the cannula was opened in order to remove any gastric juice or food remnants. If necessary, the stomach was cleansed with 40 to 50 ml lukewarm water. The ultrathin bag of the barostat was positioned into the fundus of the stomach through the gastric cannula. In order to ensure easy unfolding of the intragastric bag during the experiment, a volume of 300-400 ml was injected twice into 20 the bag. [ ]

When during a stabilisation period of maximum 90 minutes, the gastric volume is stable during 15 minutes at a constant pressure of 6 mmHg (about 0.81 kPa), the test compound was administered subcutaneously (S.C.), or intraduodenally (I.D.). Test 25 compounds were screened, *i.e.* changes in gastric volume were measured, usually at 0.63 mg/kg. Other doses and routes were tested if a test compound was shown to be active during the screening procedure. Table C-1 summarizes the mean maximal change in volume on relaxation of the fundus, during the 1 hour observation period after S.C. or I.D. administration of the test compound (0.63 mg/kg).

30

Table C-1 :

Co. No.	Route	Maximum change in volume (ml)	Co. No.	Route	Maximum change in volume (ml)
1	S.C.	156	16	I.D.	156
3	I.D.	245	18	I.D.	21
4	S.C.	327	22	I.D.	81*
6	I.D.	301	24	I.D.	35
9	S.C.	78	25	I.D.	226*
10	S.C.	31	30	I.D.	163*
13	I.D.	118			

\* : maximum change in volume determined with a concentration of 0.04 mg/kg of test compound

5

### C.2 Vasoconstrictive activity on basilar artery

Segments of basilar arteries taken from pigs (anaesthetised with sodium pentobarbital) were mounted for recording of isometric tension in organ baths. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37°C and gassed with a mixture of 95% O<sub>2</sub> - 5% CO<sub>2</sub>. The preparations were stretched until a stable basal tension of 2 grams was obtained.


The preparations were made to constrict with serotonin (3x10<sup>-7</sup> M). The response to the addition of serotonin was measured and subsequently the serotonin was washed away. This procedure was repeated until stable responses were obtained. Subsequently the test compound was administered to the organ bath and the constriction of the preparation was measured. This constrictive response was expressed as a percentage of the response to serotonin as measured previously.

The ED<sub>50</sub>-value (molar concentration) is defined as the concentration at which a test compound causes 50% of the constrictive response obtained with serotonin. Said ED<sub>50</sub>-values are estimated from experiments on three different preparations.

Claims

## 1. A compound of formula (I)

5



a stereochemically isomeric form thereof, an *N*-oxide form thereof, a pharmaceutically acceptable acid addition salt thereof, or a quaternary ammonium salt thereof, wherein

10 -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is a bivalent radical of formula

- N=CH-CH=CH- (a-1),
- CH=N-CH=CH- (a-2),
- CH=CH-N=CH- (a-3),
- CH=CH-CH=N- (a-4),

15 -N=N-CH=CH- (a-5),

- N=CH-N=CH- (a-6),
- N=CH-CH=N- (a-7),
- CH=N-N=CH- (a-8),
- CH=N-CH=N- (a-9), or

20 -CH=CH-N=N- (a-10);

-Z<sup>1</sup>-Z<sup>2</sup>- is a bivalent radical of formula

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>- (b-1),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-O- (b-2),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>-O- (b-3),

25 -Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>-S- (b-4),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>-NH- (b-5),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>-CH<sub>2</sub>- (b-6),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- (b-7),

- Y<sup>1</sup>-C(R<sup>4</sup>)=CH- (b-8),

30 -Y<sup>1</sup>-C(R<sup>4</sup>)=CH-CH<sub>2</sub>- (b-9),

- Y<sup>1</sup>-CH(R<sup>4</sup>)-CH=CH- (b-10), or

- Y<sup>1</sup>-C(R<sup>4</sup>)=CH-CH<sub>2</sub>-CH<sub>2</sub>- (b-11), or

- Y<sup>1</sup>-CH<sub>2</sub>-CH(R<sup>4</sup>) - (b-12),

35 wherein, where possible, optionally one or two hydrogen atoms on the same or a different carbon or nitrogen atom may be replaced by hydroxy,

C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyl, or C<sub>1-6</sub>alkyl optionally substituted with halo, hydroxy, C<sub>3-6</sub>cycloalkyl or phenyl;

Y<sup>1</sup> is oxygen or sulfur;

Alk<sup>1</sup> is C<sub>1-4</sub>alkylcarbonyl, carbonylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonylC<sub>1-4</sub>alkyl, carbonyl,

5 or C<sub>1-6</sub>alkanediyl optionally substituted with hydroxy, halo, amino, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, hydroxycarbonyl, C<sub>1-4</sub>alkyloxycarbonyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyloxy, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>1-4</sub>alkyloxyimino, phenylC<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkyloxycarbonylC<sub>1-6</sub>alkenyl, cyanoC<sub>1-6</sub>alkenyl or C<sub>1-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;


10 R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>1-6</sub>alkyloxy, hydroxycarbonyl, trihalomethyl, trihalomethoxy, halo, hydroxy, cyano, nitro, amino, C<sub>1-6</sub>alkylcarbonylamino,

15 C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxy, aminocarbonyl, mono- or di(C<sub>1-6</sub>alkyl)aminocarbonyl, aminoC<sub>1-6</sub>alkyl, mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxy-carbonyloxy, or C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;


18 R<sup>4</sup> is hydrogen, hydroxycarbonyl, phenyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl,

20 N-pyrolidinylcarbonyl, N-piperidinylcarbonyl, N-homopiperidinylcarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkyloxycarbonylC<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, or C<sub>1-6</sub>alkyl optionally substituted with hydroxy, cyano, amino, phenyl, mono- or di(C<sub>1-4</sub>alkyl)amino, or mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl;


25 -A- is a bivalent radical of formula




(c-1)




(c-2)



(c-3)



(c-4)



wherein  $m$  is 0 or 1;

5 Alk<sup>2</sup> is a bivalent radical independently selected from C<sub>1-4</sub>alkylcarbonylC<sub>1-4</sub>alkyl; phenyl; C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy; C<sub>3-8</sub>cycloalkanediyl optionally substituted with one or more halo, hydroxy, hydroxycarbonyl, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, phenyl; or


10 C<sub>1-6</sub>alkyl optionally substituted with one or more hydroxy, halo, amino, hydroxycarbonyl, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy, C<sub>3-6</sub>cycloalkyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, or

15 C<sub>1-6</sub>alkyl wherein the C<sub>1-6</sub>alkyl together with the carbon atom to which it is attached may form a C<sub>3-6</sub>cycloalkyl;

R<sup>6</sup> is hydrogen, C<sub>1-4</sub>alkyl, halo, hydroxy, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy, aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyl, amino, hydroxycarbonyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, or

20 C<sub>3-6</sub>cycloalkylcarbonyloxyC<sub>1-4</sub>alkyloxycarbonyloxy;

R<sup>5</sup> is a radical of formula



wherein  $n$  is 1 or 2;

25 p<sup>1</sup> is 0, and p<sup>2</sup> is 1 or 2; or p<sup>1</sup> is 1 or 2, and p<sup>2</sup> is 0;  
 X is oxygen, sulfur, NR<sup>9</sup> or CHNO<sub>2</sub>;  
 Y<sup>2</sup> is oxygen or sulfur;  
 R<sup>7</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl or phenylmethyl;  
 R<sup>8</sup> is C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl or phenylmethyl;

30 R<sup>9</sup> is cyano, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>1-6</sub>alkyloxycarbonyl or aminocarbonyl;

R<sup>10</sup> is hydrogen or C<sub>1-6</sub>alkyl;

or R<sup>9</sup> and R<sup>10</sup> taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, or morpholinyl group, optionally substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy;


5 and

Q is a bivalent radical of formula

-CH <sub>2</sub> -CH <sub>2</sub> -	(e-1),	-CO-CH <sub>2</sub> -	(e-6),
-CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -	(e-2),	-(CH <sub>2</sub> ) <sub>2</sub> -CO-	(e-7),
-CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> -	(e-3),	-CO-(CH <sub>2</sub> ) <sub>2</sub> -	(e-8),
-CH=CH-	(e-4),	-CO-CH <sub>2</sub> -CO-	(e-9),
-CH <sub>2</sub> -CO-	(e-5),	-CH <sub>2</sub> -CO-CH <sub>2</sub> -	(e-10),

10 wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C<sub>1-4</sub>alkyl, hydroxy or phenyl, or

Q is a bivalent radical of formula



15

(e-11)

(e-12)

2. A compound as claimed in claim 1 wherein R<sup>5</sup> is a radical of formula (d-1) wherein X is oxygen, and Q is a radical of formula (e-2) or (e-5).

20 3. A compound as claimed in claim 1 wherein the bivalent radical -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is of formula (a-1), (a-2) or (a-4); the bivalent radical -Z<sup>1</sup>-Z<sup>2</sup>- is of formula (b-1), (b-2) or (b-4) wherein R<sup>4</sup> is hydrogen; Alk<sup>1</sup> is -CH<sub>2</sub>-; the bivalent radical -A- is of formula (c-1) or (c-2); and R<sup>5</sup> is a radical of formula (d-1) wherein X is oxygen, R<sup>7</sup> is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

25 4. A compound according to claim 1 wherein the bivalent radical -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is of formula (a-1), (a-2) or (a-4); the bivalent radical -Z<sup>1</sup>-Z<sup>2</sup>- is of formula (b-1), (b-2) or (b-4) wherein R<sup>4</sup> is hydrogen; Alk<sup>1</sup> is -CH<sub>2</sub>-; the bivalent radical -A- is of formula (c-2) wherein R<sup>6</sup> is hydroxymethyl; and R<sup>5</sup> is a radical of formula (d-1) wherein X is oxygen, R<sup>7</sup> is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

30 5. A compound according to claim 1 wherein the bivalent radical -a<sup>1</sup>=a<sup>2</sup>-a<sup>3</sup>=a<sup>4</sup>- is of formula (a-1), (a-2) or (a-4); the bivalent radical -Z<sup>1</sup>-Z<sup>2</sup>- is of formula (b-1), (b-2) or (b-4) wherein R<sup>4</sup> is hydrogen; Alk<sup>1</sup> is -CH<sub>2</sub>-; the bivalent radical -A- is of formula

-CH<sub>2</sub>-CHOH-CH<sub>2</sub>-; and R<sup>5</sup> is a radical of formula (d-1) wherein X is oxygen, R<sup>7</sup> is hydrogen, and Q is (e-1), (e-2), (e-5) or (e-7).

6. A compound as claimed in claim 1 wherein the compound is

5      1-[1-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]-4-piperidinyl]-2-imidazolidinone;

1-[1-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]-4-piperidinyl]tetrahydro-2(1*H*)-pyrimidinone;

10     1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]amino]propyl]dihydro-2,4(1*H,3H*)-pyrimidinedione; and

1-[3-[(2,3-dihydro[1,4]dioxino[2,3-*b*]pyridin-3-yl)methyl]amino]propyl]-2,4-imidazolidinedione, a pharmaceutically acceptable acid addition salt, a stereochemically isomeric form, or an *N*-oxide form thereof.

15     7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 6.


8. A process for preparing a pharmaceutical composition as claimed in claim 7 wherein a therapeutically active amount of a compound as claimed in any of claims 1 to 6 is

20     intimately mixed with a pharmaceutically acceptable carrier.


9. A compound as claimed in any of claims 1 to 6 for use as a medicine.

10. A process for preparing a compound of formula (I) wherein

25     a) an intermediate of formula (II) is alkylated with an intermediate of formula (III) in a reaction-inert solvent and, optionally in the presence of a suitable base,




30     b) an intermediate of formula (IV), wherein Alk<sup>1'</sup> represents a direct bond or C<sub>1-5</sub>alkanediyl, is reductively alkylated with an intermediate of formula (III);



c) an intermediate of formula (V), wherein Alk<sup>1'</sup> represents a direct bond or C<sub>1-5</sub>alkanediyl, is reacted with an intermediate of formula (III);

5



in the above reaction schemes the radicals -Z<sup>1</sup>-Z<sup>2</sup>-; R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, Alk<sup>1</sup> and Alk<sup>2</sup> are as defined in claim 1 and W is an appropriate leaving group;

10

d) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into an acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

## INTERNATIONAL SEARCH REPORT

Inte ial Application No  
PCT/EP 01/06749A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D491/06 A61K31/435 C07D491/04 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 29687 A (JANSSEN PHARMACEUTICA) 17 June 1999 (1999-06-17) page 10, line 32 -page 12, line 5; claims; examples ----	1-9
A	WO 93 17017 A (JANSSEN PHARMACEUTICA) 2 September 1993 (1993-09-02) cited in the application page 13, line 25 - line 34; claims; examples ----	1-9
A	WO 97 28157 A (PIERRE FARBE MEDICAMENT) 7 August 1997 (1997-08-07) cited in the application page 1, line 4 - line 11; claims; examples ----	1-9

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 October 2001

Date of mailing of the international search report

25/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

## INTERNATIONAL SEARCH REPORT

Inte al Application No  
PCT/EP 01/06749

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 004 358 A (CIBA-GEIGY) 3 October 1979 (1979-10-03) cited in the application page 2, paragraph 5 -page 4, paragraph 1; claims; examples ---	1-9
A	US 3 910 930 A (JANSSEN ET. AL.) 7 October 1975 (1975-10-07) cited in the application column 12, line 50 - line 60; claims; examples ---	1-9
A	T. ARAKAWA ET. AL.: "New Aspects of Gastric Adaptive Relaxation, Reflex after Food Intake for More Food: Involvement of Capsaicin-sensitive Sensory Nerves and Nitric Oxide." JOURNAL OF SMOOTH MUSCLE RESEARCH, vol. 33, no. 3, 1997, pages 81-8, XP000943798 whole article ---	1-9
P, Y	WO 00 75137 A (JANSSEN PHARMACEUTICA) 14 December 2000 (2000-12-14) claims; examples ---	1-10
P, Y	WO 00 75136 A (JANSSEN PHARMACEUTICA) 14 December 2000 (2000-12-14) claims; examples -----	1-10

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/06749

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9929687	A	17-06-1999	AU 2412799 A BG 104372 A BR 9814256 A CN 1280577 T EE 200000328 A WO 9929687 A1 EP 1036073 A1 HR 20000340 A1 NO 20002074 A PL 341007 A1 TR 200001542 T2 US 6133277 A	28-06-1999 29-12-2000 03-10-2000 17-01-2001 15-08-2001 17-06-1999 20-09-2000 30-04-2001 02-06-2000 12-03-2001 22-01-2001 17-10-2000
WO 9317017	A	02-09-1993	AP 416 A AT 138064 T AU 3499193 A BG 62052 B1 BG 98870 A CA 2117483 A1 CN 1079470 A , B CZ 9402020 A3 DE 69302687 D1 DE 69302687 T2 DK 639192 T3 EE 3029 B1 WO 9317017 A1 EP 0639192 A1 ES 2087721 T3 FI 943928 A GR 3019927 T3 HR 930235 A1 HU 71129 A2 HU 9500317 A3 IL 104868 A JP 2779268 B2 JP 7504408 T KR 190300 B1 LT 3049 B LV 10715 A LV 10715 B MX 9301053 A1 NO 943186 A NZ 249124 A OA 10095 A PL 174736 B1 RO 115630 B1 RU 2121999 C1 SG 47763 A1 SI 9300097 A SK 102994 A3 US 5541180 A US 5624952 A US 5607949 A US 5688952 A ZA 9301404 A	29-09-1995 15-06-1996 13-09-1993 29-01-1999 31-03-1995 02-09-1993 15-12-1993 18-01-1995 20-06-1996 14-11-1996 19-08-1996 17-06-1996 02-09-1993 22-02-1995 16-07-1996 26-08-1994 31-08-1996 31-10-1997 28-11-1995 28-09-1995 04-01-1998 23-07-1998 18-05-1995 01-06-1999 25-10-1994 20-06-1995 20-12-1995 31-03-1994 29-08-1994 28-08-1995 18-12-1996 30-09-1998 28-04-2000 20-11-1998 17-04-1998 30-09-1993 11-07-1995 30-07-1996 29-04-1997 04-03-1997 18-11-1997 26-08-1994
WO 9728157	A	07-08-1997	FR 2744451 A1 AU 1606197 A	08-08-1997 22-08-1997

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 01/06749

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9728157	A	WO	9728157 A1	07-08-1997
EP 0004358	A 03-10-1979	AR AR AR AR AT AT AT AT AT AT AU AU DD DE DK EP ES ES ES ES FI GB GR HU IE IL JP MY NO NZ PL PT ZA ZA	227272 A1 231638 A1 227400 A1 227527 A1 372088 B 204479 A 352382 A 352482 A 352582 A 529838 B2 4524379 A 142341 A5 2961738 D1 113079 A 0004358 A1 478662 A1 484570 A1 484571 A1 484572 A1 790894 A , B, 2019837 A , B, 71865 A1 182941 B 48258 B1 56908 A 54157570 A 12287 A 790917 A , B, 189939 A 214206 A1 69369 A 7900417 A 7901276 A	15-10-1982 31-01-1985 29-10-1982 15-11-1982 25-08-1983 15-01-1983 15-08-1985 15-08-1985 15-08-1985 23-06-1983 27-09-1979 18-06-1980 25-02-1982 21-09-1979 03-10-1979 16-01-1980 16-05-1980 16-05-1980 16-05-1980 21-09-1979 07-11-1979 07-07-1983 28-03-1984 14-11-1984 30-09-1983 12-12-1979 31-12-1987 21-09-1979 15-12-1981 25-02-1980 01-04-1979 30-01-1980 26-03-1980
US 3910930	A 07-10-1975	AU BE DE FR JP NL US ZA	6418474 A 809410 A2 2400094 A1 2213059 A1 49095980 A 7400132 A 3929801 A 7400060 A	10-07-1975 04-07-1974 18-07-1974 02-08-1974 11-09-1974 08-07-1974 30-12-1975 27-08-1975
WO 0075137	A 14-12-2000	AU WO	4568500 A 0075137 A1	28-12-2000 14-12-2000
WO 0075136	A 14-12-2000	AU WO	5525600 A 0075136 A1	28-12-2000 14-12-2000